S2WA4003.

Study characteristics
Methods	Multicentre, R, DB, PC, parallel‐group. Single dose to treat single attack; several attacks treated over 12 weeks Medication taken when PI ≥ moderate Assessments at 0, 4 h, for efficacy and adverse events, MSQ at baseline and after 12 weeks of treatment
Participants	Migraine ± aura (IHS 1988), aged 18‐65 years. History: > 12 months with frequency of 1‐6 per month and untreated severity ≥ moderate Excluded: previous use of triptan on > 3 occasions or had prescription for sumatriptan, ischaemic disease or symptoms, cardio‐ or cerebrovascular pathology, uncontrolled hypertension, epilepsy N = 168 F = 85% Mean age 39 years
Interventions	Naproxen sodium 275 mg, n = 81 Naratriptan 2.5 mg, n = 87
Outcomes	Adverse events Withdrawals
Notes	Oxford Quality Score: R1, DB2, W1. Total = 4
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Double dummy" method
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"Double dummy" method
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants accounted for
Size	Unclear risk	50‐200 participants in each treatment arm